An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years
Lymphoma, Follicular
Safety: Incidence of adverse events, 3 years
Progression-free survival, 3 years|Event-free survival, 3 years|Overall survival, 3 years
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years